Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Casgevy, approved in 2023, is a medicine for two rare, life-threatening blood disorders with few treatment options. Journavx ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...